Royal Bank of Canada
MNPR icon

Royal Bank of Canada’s Monopar Therapeutics MNPR Stock Holding History

Royal Bank of Canada’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Sell
49
-277
-85% -$16.7K ﹤0.01% 6722
2025
Q4 		$22K Buy
326
+251
+335% +$20.5K ﹤0.01% 5986
2025
Q3 		$6K Buy
75
+56
+295% +$2.5K ﹤0.01% 6651
2025
Q2 		$1K Sell
19
-186
-91% -$6.75K ﹤0.01% 6903
2025
Q1 		$7K Buy
+205
New +$7.39K ﹤0.01% 6266
2024
Q2 		– Sell
-20
Closed – – 7349
2024
Q1 		$0 Buy
+20
New +$60 ﹤0.01% 7366
2023
Q2 		– Sell
-1,000
Closed -$7K – 7495
2023
Q1 		$7K Buy
+1,000
New +$14.8K ﹤0.01% 6460
2022
Q3 		– Sell
-823
Closed -$9K – 7685
2022
Q2 		$9K Hold
823
– – ﹤0.01% 6429
2022
Q1 		$10K Hold
823
– – ﹤0.01% 6947
2021
Q4 		$13K Hold
823
– – ﹤0.01% 6974
2021
Q3 		$20K Sell
823
-203
-20% -$5.25K ﹤0.01% 6707
2021
Q2 		$30K Sell
1,026
-800
-44% -$22.9K ﹤0.01% 6344
2021
Q1 		$57K Buy
+1,826
New +$66.7K ﹤0.01% 5799

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's MNPR Position: Q1 2026 in Review

Royal Bank of Canada reduced its Monopar Therapeutics (MNPR) stake by 85% in Q1 2026, selling an estimated $16.7K and leaving 49 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6722.

Royal Bank of Canada first reported a position in MNPR in Q1 2021 and has held it in 13 quarters since. The position peaked at $57K in Q1 2021. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Royal Bank of Canada held 49 shares of Monopar Therapeutics worth $2K as of Q1 2026.
  • Royal Bank of Canada sold 277 Monopar Therapeutics shares in Q1 2026, an estimated $16.7K.
  • Monopar Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6722 holding.
  • Royal Bank of Canada first reported a position in Monopar Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • Royal Bank of Canada's Monopar Therapeutics position peaked at $57K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.